- ScreenPro (SCRN) has launched its cost-effective rapid antigen test for COVID-19
- The initiative lowers the financial barrier to as little as C$60 per test
- The test yields 94 per cent sensitivity and provides results in 10 minutes
- ScreenPro Security provides turnkey coronavirus screening solutions to the private sector
- ScreenPro (SCRN) is down 4.54 per cent and is currently trading at $0.105 per share
ScreenPro (SCRN) has launched its cost-effective rapid antigen test for COVID-19.
The initiative lowers the financial barrier for testing to as little as C$60 per test, thus ensuring that more Canadians can have peace of mind during the COVID-19 pandemic.
The test requires a trained nurse to collect a sample from a patient using a nasal swab. With over 94 per cent sensitivity, results are available in just 10 minutes.
When compared with polymerase chain reaction testing, rapid testing enables employers to test larger groups of employees in less time at a significantly lower cost.
The company views its test as a turnkey solution to ensure everyone in a controlled space has a negative test result prior to entry.
John McMullen, ScreenPro’s CEO, commented,
“Businesses need an effective and cost-efficient way to reset and restart their businesses. Rapid testing is one of the most widely in-demand processes and we have the platform and solution to achieve our common goal, back to work. Our test picks up the new variants and with the rapid spread of this third wave, testing is more important than ever.”
ScreenPro Security provides turnkey coronavirus screening solutions to the private sector.
ScreenPro (SCRN) is down 4.54 per cent and is currently trading at $0.105 per share as of 10:13 am ET.
